Nimesulide Doc Generici

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nimesulide Doc Generici

Quick Facts

Property Description
Active ingredient Nimesulide
Form Granules for oral suspension, tablets, capsules
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common purpose Symptomatic relief of pain and inflammation
Origin Synthetic (Sulfonanilide class)

What Type of Medicine is Nimesulide Doc Generici?

Nimesulide Doc Generici is a generic medicinal product containing the single active substance Nimesulide. It is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Chemically, Nimesulide is a synthetic compound belonging to the sulfonanilide family, with the molecular formula C13H12N2O5S. The term "Doc Generici" identifies the manufacturer, signifying that the drug meets the same standards of quality and bioequivalence as the original reference product.


Composition, Unique Action, and General Purpose

The active component Nimesulide is prepared for oral route administration and is supplied in several dosage forms, including granules for oral suspension, as well as various tablets and capsules. The drug's mechanism is clinically recognized: it is categorized as a preferential Cyclooxygenase-2 (COX-2) selective inhibitor. This action means the drug primarily targets the COX-2 enzyme, which drives the chemical processes leading to pain and inflammation, distinguishing it from traditional non-selective NSAIDs.

Nimesulide's profile establishes its generalized role as an agent for managing acute pain and inflammation. Consequently, the general purpose of Nimesulide Doc Generici is to provide comprehensive symptomatic relief via its anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effects. Its functional profile is established for rapidly diminishing the three major components of acute discomfort.

Regulatory References

  1. Nimesulide - referral | European Medicines Agency (EMA)

What side effects are possible with Nimesulide Doc Generici?

The safety profile of Nimesulide Doc Generici is defined by adverse reactions documented in official regulatory sources, classified by frequency and affected body system. As a Non-Steroidal Anti-Inflammatory Drug (NSAID), its profile includes risks common to that class, alongside specific concerns regarding hepatotoxicity.

Adverse Reaction Scope

Classification Examples of Documented Adverse Reactions System-Organ Class Involved
Common (ge 1/100) Diarrhoea, Nausea, Vomiting, Increased hepatic enzyme values Gastrointestinal, Hepatobiliary
Uncommon (ge 1/1,000) Constipation, Flatulence, Gastritis, Hypertension, Oedema Gastrointestinal, Vascular
Very Rare (< 1/10,000) Thrombocytopenia, Acute Renal Failure, Stevens-Johnson syndrome Blood, Renal, Skin

Serious Adverse Reactions and Constraints

Officially documented serious risks include Gastrointestinal Haemorrhage, Ulceration, and Perforation, which can occur at any time. The medicine is also associated with Hepatotoxicity, including very rare cases of fatal hepatic failure. Severe skin reactions such as Toxic Epidermal Necrolysis are also listed as very rare events.

Use is contraindicated in individuals with severe hepatic impairment, severe renal impairment, active peptic ulcer or bleeding disorders, and severe heart failure. Older adults are specifically noted in regulatory documents as being more susceptible to the gastrointestinal and renal adverse effects of NSAIDs.

Dose- and Exposure-Related Patterns

Regulatory authorities mandate that the undesirable effects be minimized by using the minimum effective dose for the shortest duration necessary. The maximum duration of a treatment course is limited to 15 days to mitigate the risk of developing liver problems, as noted in the European regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is based on official government regulatory documents detailing the documented manifestations of acute overdose and the required management approach.


Documented Manifestations of Overdose

Symptoms following an acute overdose of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like Nimesulide are usually limited to effects on the gastrointestinal tract and central nervous system:

  • Gastrointestinal: Epigastric pain, nausea, vomiting, and in some cases, gastrointestinal bleeding.
  • Central Nervous System: Lethargy and drowsiness.

Risk of Severe Outcomes

While uncommon, severe outcomes may occur following an overdose and necessitate immediate medical evaluation. These rare complications include:

  • Systemic: Acute renal failure, hypertension, respiratory depression, and coma.
  • Hypersensitivity: Anaphylactoid reactions have been reported with NSAID ingestion and may occur following an overdose.

Required Action and Management

Seek immediate medical attention if any of the severe manifestations listed above are suspected or confirmed. The official approach to management is as follows:

  • Antidote: There are no specific antidotes available for Nimesulide overdose.
  • Care: Patients must be managed by symptomatic and supportive care to address the effects as they appear.

Therapeutic Uses of Nimesulide Doc Generici

What Nimesulide Doc Generici Treats: Main Uses and Benefits

This medication may be relevant for the short-term, symptomatic management of acute pain and inflammation arising from various origins. Its clinical applicability includes addressing the discomfort associated with acute pain, the symptoms of painful osteoarthritis flare-ups, and the spasmodic pain of primary dysmenorrhoea (menstrual cramps).

Nimesulide Doc Generici provides supportive relief across multiple symptomatic domains by contributing to analgesic, anti-inflammatory, and antipyretic effects. This approach is relevant in settings marked by increased discomfort.

“The medication may assist with easing the overall symptom burden during periods of acute physiological strain.”

This symptomatic management may be relevant in situations where symptoms present episodically or intensify temporarily, such as after minor trauma or during acute illness, and may assist with support during difficult episodes.


Quick Fact: Relief for Acute Discomfort

Symptom Domain Key Benefit Context
Pain Analgesic support Acute, mild to moderate episodes
Inflammation Anti-inflammatory relief Swelling, redness associated with injury
Fever Antipyretic action Elevated body temperature

Regulatory References

  1. European Medicines Agency Summary of Product Characteristics

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Nimesulide Doc Generici is authorized for use in adults and adolescents aged 12 years and older as a second-line treatment. Elderly patients and those with mild to moderate renal impairment (creatinine clearance of 30-80 mL/min) are generally allowed without a mandated dosage reduction.


Absolute Contraindications

Use is strictly contraindicated and must be avoided in the following groups, as established in regulatory labeling:

  • Age and Development: Children under 12 years, pregnant women in the third trimester, and breastfeeding women.
  • Organ Function: Patients with hepatic impairment or severe renal impairment (creatinine clearance < 30 mL/min).
  • Pre-existing Pathology: Patients with severe heart failure, severe coagulation disorders, or active gastrointestinal ulcers, bleeding, or a history of recurrent ulceration.
  • Other: Individuals with a history of hepatotoxic reactions to nimesulide or known hypersensitivity to other NSAIDs.

Eligibility Rules and Limitations

For eligible populations, regulatory documentation imposes specific constraints:

  • Treatment Position: The medicine is restricted to second-line treatment only.
  • Treatment Duration: The maximum treatment course is 15 days.
  • Specific Conditions: Use for painful osteoarthritis is no longer prescribed as the risk-benefit balance is not considered favorable for this chronic condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Nimesulide defines potential interactions based on both pharmacodynamic (PD) and pharmacokinetic (PK) mechanisms, leading to specific restrictions on concomitant use.


High-Risk Combinations and Restrictions

Category Specific Interacting Agents/Classes Interaction Type & Consequence
Contraindicated Other potentially hepatotoxic substances Risk of serious liver injury.
Not Recommended Warfarin or similar oral anticoagulants, Acetylsalicylic acid (ASA) Increased risk of bleeding/haemorrhage due to additive PD effect.
Not Recommended Other Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Increased risk of gastrointestinal adverse effects and general toxicity.

Interactions Requiring Caution and Monitoring

Nimesulide may significantly alter the exposure of certain co-administered drugs:

  • Lithium and Methotrexate: Concomitant use may lead to increased plasma concentrations of Lithium and Methotrexate, requiring close therapeutic monitoring.
  • Diuretics (e.g., Furosemide) and Antihypertensives (e.g., ACE Inhibitors, Beta-blockers): Nimesulide can reduce the natriuretic and diuretic effect of Furosemide and diminish the antihypertensive effects of ACE Inhibitors and Beta-blockers. Caution is required, particularly in susceptible renal or cardiac patients.
  • Cyclosporine: Co-administration requires caution, as Nimesulide may affect renal haemodynamics.

In cases where combination with anticoagulants cannot be avoided, official documentation requires close monitoring of anticoagulant activity (e.g., INR) due to the heightened bleeding risk.

Mechanism of Action

Selective Modulation of Prostaglandin Synthesis

The drug acts as a selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This mechanism blocks the initial step in the prostaglandin synthesis pathway, preventing the formation of key pro-inflammatory mediators, specifically PGE2. This targeted suppression of PGE2 synthesis modulates the molecular signaling cascades that contribute to nerve sensitization and hypothalamic temperature regulation.

Influence on Oxidative Stress and Tissue Integrity

Nimesulide's mechanism extends beyond the COX enzymes, influencing oxidative stress pathways through its ability to scavenge specific free radicals (Reactive Oxygen Species). It also modulates the activity of certain Matrix Metalloproteinases ( MMPs), which are enzymes involved in the remodeling of the extracellular matrix. These non-prostaglandin actions contribute to the alteration of cellular signaling pathways, which influences the overall biological response cascade.

Mechanistic Cascade to Systemic Effect

The molecular inhibition of PGE2 formation initiates a sequence that reduces local vasodilation and decreases the chemical sensitization of peripheral nerve endings. This early molecular step influences the systemic physiological outcome by modulating the pathways that contribute to nerve sensitization and local vascular changes, thereby defining the resulting pharmacological effect profile.

Dosage and Administration Information

How to Use Nimesulide Doc Generici

Administration of Nimesulide Doc Generici follows a standardized protocol for proper use. The medicine is primarily available in oral dosage forms, such as tablets, capsules, and granules for oral suspension, intended for systemic administration.


Dosing and Frequency Protocol

The standard protocol for systemic use requires the lowest effective amount for the shortest possible duration. The usual dose for adults is 100 mg, to be taken twice a day (bid). The total amount administered over 24 hours is not to exceed the maximum daily dose of 200 mg.


Context and Course Duration

Oral formulations of Nimesulide are intended to be taken after a meal to fulfill the necessary administration timing. This medicine is designated for short-term administration. The maximum duration of a single treatment course is 15 days.


Use in Specific Populations

Population Group Administration Guideline
Adolescents (12 to 18 years) No dosage adjustment is necessary.
Older Adults No dosage adjustment is typically required.
Children (under 12 years) Systemic use is contraindicated.
Severe Impairment Use is contraindicated in severe hepatic or renal impairment.

These parameters define a standardized use protocol focused on fixed dosage, defined frequency, meal timing, and a clear time-limit for the course of administration.

Recent Clinical Evidence

Clinical studies have provided data on the effectiveness of nimesulide in specific acute painful and inflammatory conditions. This evidence is crucial for understanding its role as a non-steroidal anti-inflammatory drug (NSAID) with preferential cyclooxygenase-2 (COX-2) inhibitory activity.


Outcomes in Acute Pain and Dysmenorrhea

Nimesulide's effectiveness has been primarily studied in the management of acute pain and primary dysmenorrhea (menstrual pain). Clinical trial results indicate that nimesulide consistently demonstrates effectiveness greater than placebo for these approved uses. Findings suggest the substance has a rapid onset of analgesic action, which may offer an advantage in the treatment of acute pain requiring swift relief.

Comparative studies have shown nimesulide to be generally comparable in efficacy to other established NSAIDs. In some clinical trials, nimesulide has been found to be non-inferior, or in some instances, to provide superior pain relief compared to certain common NSAIDs, particularly concerning the speed of action in acute settings.


Safety Profile and Regulatory Review

Following comprehensive reviews by regulatory bodies, the use of systemic nimesulide-containing medicines has been restricted to the shortest possible duration, typically up to 15 days, due to concerns regarding the risk of liver toxicity (hepatotoxicity). The European Medicines Agency (EMA) concluded that the benefits of nimesulide continue to outweigh its risks, provided that its use is strictly limited to the treatment of acute pain and primary dysmenorrhea. Studies have suggested that nimesulide may have a favorable safety profile concerning gastrointestinal side effects when compared to certain non-selective NSAIDs.

Frequently Asked Questions (FAQ)

Common questions about Nimesulide Doc Generici (FAQ)


Q: How quickly do people typically say they feel the effects of Nimesulide Doc Generici?

Official information regarding its function describes the active substance, Nimesulide, as being characterized by a fast onset of analgesic activity (pain-relieving effect). This is one of the features studied in its use for acute pain management.


Q: Are there different strengths or formats (like tablets vs. granules) for Nimesulide Doc Generici?

Yes, Nimesulide Doc Generici is commonly supplied in several oral forms. These include tablets and granules for oral suspension, both typically containing 100 mg of the active ingredient. Official product information confirms the availability of these different formats.


Q: What kind of stomach issues are sometimes mentioned by people taking Nimesulide Doc Generici?

According to official documentation on undesirable effects, the most commonly reported gastrointestinal issues include diarrhoea, nausea, and vomiting. Less commonly, some people report effects such as constipation, flatulence, and gastritis (stomach irritation).


Q: What are the less common side effects associated with Nimesulide Doc Generici?

Regulatory documents list side effects that are considered less common. Examples of these less common documented effects include changes like hypertension (high blood pressure) and the presence of oedema (fluid retention or swelling).


Q: Are there any foods or drinks that should be avoided when taking Nimesulide Doc Generici?

Official regulatory documents specifically caution that alcohol abuse and a history of alcoholism must be avoided during treatment. This is primarily due to the potential for alcohol consumption to increase the risk of liver-related reactions while using this drug.


Q: Is Nimesulide Doc Generici typically given to children?

No, the official regulatory guidelines specify that the use of this medicine is contraindicated in children who are under 12 years of age.


Q: Are there any specific organs the official documents highlight as needing monitoring while taking Nimesulide Doc Generici?

Regulatory warnings highlight the importance of assessing and monitoring patient concerns related to liver function (hepatic system), renal function (kidneys), and the gastrointestinal tract (stomach and intestines). This is because Nimesulide, like other NSAIDs, can impact these systems.


Q: Do patients sometimes experience skin reactions after taking Nimesulide Doc Generici?

Yes, regulatory documents list skin reactions as possible undesirable effects. While less common effects like simple rash may occur, severe skin reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, are documented as very rare events.


Q: Can Nimesulide Doc Generici interact with psychiatric medications?

Official product information notes specific drug interactions that require caution. This includes an interaction with Lithium, which is a substance used in the management of certain psychiatric conditions.


Q: Are there different instructions for taking the granules versus the tablets of Nimesulide Doc Generici?

Regulatory documents indicate that the granules for oral suspension are typically prepared by dissolving them in water. Tablets are generally intended to be swallowed whole.


Q: What happens if I forget to take a dose of Nimesulide Doc Generici?

Official principles for short-term use emphasize adhering to the established maximum daily limit. The procedure for a missed dose is typically to avoid compensating by increasing the subsequent amount and to proceed with the next scheduled dose.


Q: Is it okay to take Nimesulide Doc Generici with simple nutritional supplements?

Regulatory interaction documents focus primarily on other medicines. However, a general caution is noted in medical practice regarding the use of other analgesics or NSAIDs simultaneously with this medicine.


Q: Does taking Nimesulide Doc Generici for a long time change the way it affects the body?

Official regulatory authorities mandate that treatment should be limited to the shortest possible duration, with a maximum course of 15 days. This strict time limit is in place due to concerns about the risk of liver problems associated with prolonged use.


Q: What pain types (like joint pain or headache) do patients frequently report using Nimesulide Doc Generici for?

Beyond the officially approved uses of acute pain and primary dysmenorrhea, regulatory documents in various regions list its use for conditions such as dental pain, headache, and certain musculoskeletal disorders like tendinitis.


Q: Does Nimesulide Doc Generici have an effect on sleep or alertness?

Official warnings state that if a patient experiences side effects like dizziness, vertigo, or somnolence (drowsiness), caution should be exercised regarding activities requiring complete focus, such as driving or operating machinery.


Q: What is the significance of Nimesulide Doc Generici being a 'generic' medicine?

Being a generic medicine means the product contains the same active substance, Nimesulide, and is required by regulatory bodies to meet the same standards of quality and bioequivalence as the original brand-name reference product.


Q: How long does Nimesulide Doc Generici stay in the system after the last dose?

Based on official pharmacokinetic information, the half-life of the active substance, Nimesulide, is reported to be approximately 1.56 to 4.95 hours. The half-life of its active metabolite is similar.


Q: Is it true that Nimesulide Doc Generici is not approved in certain countries?

Yes, the regulatory status of the active substance, Nimesulide, varies globally. For instance, the drug is not approved for marketing in the United States by the FDA, but it is approved with restrictions in numerous countries that follow European Medicines Agency (EMA) guidelines.


Q: What is the typical age range of people who are prescribed Nimesulide Doc Generici?

Official regulatory documents indicate that the medicine is authorized for use in adults and adolescents aged 12 years and older. Its use is strictly limited to these age groups.


Q: Why is Nimesulide Doc Generici sometimes described as a selective COX-2 inhibitor?

It is classified this way because its primary action is a preferential targeting of the Cyclooxygenase-2 (COX-2) enzyme. This enzyme is known to be primarily involved in chemical pathways that lead to pain and inflammation.


Q: Does Nimesulide Doc Generici have any known interactions with herbal teas or remedies?

While regulatory documents specifically detail interactions with prescribed medicines, general practice emphasizes that individuals should inform their prescribing professional about all medicines, supplements, or herbals they are taking, to allow for assessment of possible interactions.


Q: What are the signs of taking too much Nimesulide Doc Generici?

Official information regarding overdose notes that symptoms may include feelings of lethargy or drowsiness, nausea, vomiting, and pain in the upper abdomen, known as epigastric pain.


Q: Are there official warnings about driving or operating machinery while on Nimesulide Doc Generici?

Official warnings indicate that activities such as driving or operating machinery should be avoided if side effects such as dizziness, vertigo, or somnolence are experienced.


Q: Do people with asthma need to be careful when using Nimesulide Doc Generici?

Yes, the use of this medicine is contraindicated (must be avoided) in individuals who have a history of hypersensitivity reactions, such as bronchial asthma, to related medicines like acetylsalicylic acid or other NSAIDs.


Q: Is it common for Nimesulide Doc Generici to be prescribed for dental pain?

In some countries where the medicine is approved, official documents list the relief of dental pain as a condition for which the drug may be used, falling under its general indication for acute pain management.


Q: What is the common reason for Nimesulide Doc Generici to be available only by prescription?

The medicine is restricted to prescription-only status primarily because regulatory bodies require a healthcare professional to carefully assess the patient's overall risk profile before prescribing. This is necessary to mitigate potential serious risks, particularly concerning liver toxicity.


Q: What is the general patient feedback about the taste of the Nimesulide Doc Generici granules?

While direct patient review is not included in official documents, the product characteristics for the oral granules often indicate the inclusion of a specific flavouring, such as an orange flavour excipient.


Q: Do studies suggest any long-term effects of using Nimesulide Doc Generici?

Official regulatory guidelines strictly limit the duration of use to a maximum of 15 days. This time restriction exists because the risk-benefit profile is not considered favorable for chronic or long-term conditions, mainly due to potential liver risk.


Q: Is the onset of action different when taken with or without food?

Official instructions specify that the medicine must be taken after a meal. While regulatory documents mandate this timing, they do not specifically detail the difference in the speed of action if it were taken otherwise.


Q: Is Nimesulide Doc Generici a narcotic or opioid painkiller?

No, Nimesulide Doc Generici is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It works through a different mechanism and is not part of the narcotic or opioid class of painkillers.

How should Nimesulide Doc Generici be stored and disposed of?

How to Store and Dispose of Nimesulide Doc Generici

The storage and disposal of Nimesulide Doc Generici must adhere to official regulatory requirements to ensure product quality and public safety.


Storage Requirements

The product should be stored out of the sight and reach of children.

Storage conditions require keeping the medicine in its original container with the closure tightly closed to protect it from moisture. The product must be stored below 30 C and protected from direct heat and sunlight. It is also specified not to refrigerate or freeze the medicine.


Disposal Instructions

Unused or expired Nimesulide Doc Generici must not be thrown into household trash or released into wastewater and the environment. Disposal must follow official guidelines, which typically require returning the medicine to a pharmacy take-back scheme or a designated approved waste collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nimesulide Doc Generici found in:

A-Z Index: